Amol Akhade, Senior Consultant at Fortis Hospitals Mumbai, shared on X:
“ESMO 2026 / TroFuse-005 (LBA11): Sacituzumab tirumotecan (Sac-TMT), a TROP2-directed ADC, delivers both PFS and OS benefit!
Phase 3 / N=776 / Previously treated advanced/recurrent endometrial cancer after platinum + immunotherapy.
Sac-TMT vs Physician’s Choice:
- Median PFS: 7.2 vs 3.9 months (HR 0.59; p<0.0001)
- Median OS: 19.0 vs 12.1 months (HR 0.68; p=0.0001)
- ORR: 35.1% vs 17.3%
- Median DoR: 11.1 vs 6.9 months
- Grade ≥3 treatment-related AEs: 54.4% vs 41.4%
Take-home: A significant 6.9-month median OS improvement in a difficult-to-treat, post-immunotherapy population!”
You can also read:
